Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line

Journal of Neurochemistry

Volumn 111, Issue 5, 2009, Pages 1161-1171

  Tarozzi, Andrea ^a   Morroni, Fabiana ^a   Merlicco, Adriana ^a   Hrelia, Silvana ^a   Angeloni, Cristina ^a   Cantelli Forti, Giorgio ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antioxidant activity; Dopaminergic cells; Glutathione; Neuronal death; Oxidative stress; Sulforaphane

Indexed keywords

BUTHIONINE SULFOXIMINE; CASPASE 9; CATALASE; DNA; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HYDROGEN PEROXIDE; OXIDOPAMINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFORAPHANE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN SH SY5Y; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC ACTIVITY; HUMAN; HUMAN CELL; NECROSIS; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANTICARCINOGENIC AGENTS; CASPASE 3; CASPASE 9; CELL DEATH; CELL LINE, TUMOR; DNA FRAGMENTATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; HUMANS; HYDROGEN PEROXIDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROBLASTOMA; OXIDATIVE STRESS; OXIDOPAMINE; THIOCYANATES; TIME FACTORS;

EID: 70350761712     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06394.x     Document Type: Article

References (51)

1. Allen S., Shea J. M., Felmet T., Gadra J. Dehn P. F. (2001) A kinetic microassay for glutathione in cells plated on 96-well microtiter plates. Methods Cell Sci. 22, 305 312.
2. Angeloni C., Leoncini E., Malaguti M., Angelini S., Hrelia P. Hrelia S. (2009) Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J. Agric. Food. Chem. 57, 5615 5622.
3. Barnham K. J., Masters C. L. Bush A. I. (2004) Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205 214.
4. Bharath S., Hsu M., Kaur D., Rajagopalan S. Andersen J. K. (2002) Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64, 1037 1048.
5. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135 172.
6. Campbell L., Howie F., Arthur J. R., Nicol F. Beckett G. (2007) Selenium and sulforaphane modify the expression of selenoenzymes in the human endothelial cell line EAhy926 and protect cells from oxidative damage. Nutrition 23, 138 144.
7. Chinta S. J. Andersen J. K. (2008) Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta 1780, 1362 1367.
8. Chinta S. J., Kumar M. J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D. G., Choi J. Andersen J. K. (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 27, 13997 14006.
9. Dagnino-Subiabre A., Cassels B. K., Baez S., Johansson A. S., Mannervik B. Segura-Aguilar J. (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem. Biophys. Res. Commun. 274, 32 36.
10. Dash P. K., Zhao J., Orsi S. A., Zhang M. Moore A. N. (2009) Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci. Lett. 460, 103 107.
11. Gao X., Dinkova-Kostova A. T. Talalay P. (2001) Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the in direct antioxidant effects of sulforaphane. Proc. Natl Acad. Sci. USA 98, 15221 15226.
12. Han J. M., Lee Y. J., Lee S. Y., Kim E. M., Moon Y., Kim H. W. Hwang O. (2007) Protective effect of sulforaphane against dopaminergic cell death. Pharmacol. Exp. Ther. 321, 249 256.
13. Harada S., Fujii C., Hayashi A. Ohkoshi N. (2001) An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun. 288, 887 892.
14. Hayes J. D., Flanagan J. U. Jowsey I. R. (2005) Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51 88.
15. Hung A. Y. Schwarzschild M. A. (2007) Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr. Opin. Neurol. 20, 477 483.
16. Jenner P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol. 53, S26 S36.
17. Jenner P. Olanow C. W. (2006) The pathogenesis of cell death in Parkinson's disease. Neurology 66, S24 S36.
18. Jha N., Jurma O., Lalli G., Liu Y., Pettus E. H., Greenamyre J. T., Liu R. M., Forman H. J. Andersen J. K. (2000) Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. Biol. Chem. 275, 26096 260101.
19. Jia Z., Zhu H., Misra H. P. Li Y. (2008) Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide. Brain Res. 1197, 159 169.
20. Kamat C. D., Gadal S., Mhatre M., Williamson K. S., Pye Q. N. Hensley K. (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J. Alzheimer's Dis. 15, 473 493.
21. Kong L., Chen G. D., Zhou X., McGinnis J. F., Li F. Cao W. (2009) Molecular mechanisms underlying cochlear degeneration in the tubby mouse and the therapeutic effect of sulforaphane. Neurochem. Int. 54, 172 179.
22. Konwinski R. R., Haddad R., Chun J. A., Klenow S., Larson S. C., Haab B. B. Furge L. L. (2004) Oltipraz, 3H-1,2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells. Toxicol. Lett. 153, 343 355.
23. Kraft A. D., Johnson D. A. Johnson J. A. (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 24, 1101 1112.
24. Lin M. T. Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787 795.
25. Lotharius J. Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932 942.
26. Mattson M. P., Son T. G. Camandola S. (2007) Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response 5, 174 186.
27. Movsesyan V. A., Yakovlev A. G., Dabaghyan E. A., Stoica B. A. Faden A. I. (2002) Ceramide. Induces neuronal apoptosis through the caspase-9/caspase-3 pathway. Biochem. Biophys. Res. Comm. 299, 201 207.
28. Mukherjee S., Gangopadhyay H. Das D. K. (2008) Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily. J. Agric. Food. Chem. 56, 609 617.
29. Noyan-Ashraf M. H., Sadeghinejad Z. Juurlink B. H. (2005) Dietary approach to decrease aging-related CNS inflammation. Nutr. Neurosci. 8, 101 110.
30. Okouchi M., Ekshyyan O., Maracine M. Aw T. Y. (2007) Neuronal apoptosis in neurodegeneration. Antioxid. Redox Signal. 9, 1059 1096.
31. Prochaska H. J. Santamaria A. B. (1988) Direct measurement of NAD(P)H:Quinone reductase from cells cultures in microtiter wells, a screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328 336.
32. Ross D. (2004) Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36, 639 654.
33. Sánchez-Iglesias S., Rey P., Méndez-Alvarez E., Labandeira-García J. L. Soto-Otero R. (2007) Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem. Res. 32, 99 105.
34. Schulz J. B., Lindenau J., Seyfried J. Dichgans J. (2000) Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267, 4904 4911.
35. Shapiro T. A., Fahey J. W., Dinkova-Kostova A. T., Holtzclaw W. D., Stephenson K. K., Wade K. L. Talalay P. (2006) Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr. Cancer 55, 53 62.
36. Sharma S., Nemecz S. K., Zhu S. Steele V. E. (1997) Identification of chemiopreventive agents by screening for identification of glutathione-S- transferase as a biomarker. Methods Cell Sci. 19, 49 52.
37. Shimizu E., Hashimoto K., Komatsu N. Iyo M. (2002) Roles of endogenous glutathione levels on 6-hydroxydopamine-induced apoptotic neuronal cell death in human neuroblastoma SK-N-SH cells. Neuropharmacology 43, 434 443.
38. Siebert A., Desai V., Chandrasekaran K., Fiskum G. Jafri M. S. (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J. Neurosci. Res. 87, 1659 1669.
39. Siegel D., Anwar A., Winski S. L., Kepa J. K., Zolman K. L. Ross D. (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 59, 263 268.
40. Soto-Otero R., Méndez-Alvarez E., Hermida-Ameijeiras A., Muñoz-Patiño A. M. Labandeira-Garcia J. L. (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74, 1605 1612.
41. Tarozzi A., Morroni F., Angeloni C., Hrelia S., Marchesi A., Cantelli Forti G. Hrelia P. (2007) Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-SY5Y cells. Neurosci. Lett. 424, 36 40.
42. Trinh K., Moore K., Wes P. D., Muchowski P. J., Dey J., Andrews L. Pallanck L. J. (2008) Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J. Neurosci. 28, 465 472.
43. Vali S., Mythri R. B., Jagatha B., Padiadpu J., Ramanujan K. S., Andersen J. K., Gorin F. Bharath M. M. (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 149, 917 930.
44. Vincent A. M., Kato K., McLean L. L., Soules M. E. Feldman E. L. (2009) Sensory neurons and Schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid. Redox Signal. 3, 425 438.
45. Weber C. A. Ernst M. E. (2006) Antioxidants, supplements, and Parkinson's disease. Ann. Pharmacother. 40, 935 938.
46. Wierinckx A., Brevé J., Mercier D., Schultzberg M., Drukarch B. Van Dam A. M. (2005) Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 166, 132 143.
47. Yacoubian T. A. Standaert D. G. (2009) Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 1792, 676 687.
48. Ye L., Dinkova-Kostova A. T., Wade K. L., Zhang Y., Shapiro T. A. Talalay P. (2002) Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin. Chim. Acta 316, 43 53.
49. Zeevalk G. D., Razmpour R. Bernard L. P. (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed. Pharmacother. 62, 236 249.
50. Zhao J., Kobori N., Aronowski J. Dash P. K. (2006) Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett. 393, 108 112.
51. Zhou Z. D. Lim T. M. (2009) Roles of glutathione (GSH) in dopamine (DA) oxidation studied by improved tandem HPLC plus ESI-MS. Neurochem. Res. 34, 316 326.